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1. Introduction 
The natural product griseofulvin, (2S,6'R)-7-chloro-4,6-dimethoxybenzofuran-3-one-2-spiro-1'-(2'-
methoxy-6'-methylcyclohex-2'-en-4'-one), (1, Figure 1) has a rich chemistry dating back to the early 
1950s. Initial research was aimed at the structural elucidation of the fungal metabolite and later 
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emphasis was on synthesizing analogs for biological investigation of the antifungal properties, both by 
semisynthesis from griseofulvin and by de novo synthesis. Griseofulvin was launched on April 6, 1959 
in the US by ICI under the trade name “Fulcin” and in the UK by Glaxo as “Grisovin”.1 Griseofulvin 
has been in clinical use for treatment of ringworm in animals and humans since, and recently, 
griseofulvin has attracted renewed attention due to reports of complementary bioactivity in mammalian 
systems, including antiviral and anticancer effects. 
 
 
Figure 1. The structure of griseofulvin 1, dechlorogriseofulvin 2 and 7-bromo-7-dechloro-griseofulvin 
3, with designation of the A, B and C ring including the IUPAC recommended numbering. 
 
The chemistry of griseofulvin and analogs has not been reviewed since 1974,
2
 making an updated and 
comprehensive overview of the literature timely. Here, we present the history of griseofulvin, its 
biosynthesis, an introduction to the biology of the compound class, total synthesis of 1 and analogs, as 
well as the chemistry used to prepare analogs of griseofulvin starting from the natural product. Specific 
synthetic routes are presented in schemes to illustrate the chemistry and the analogs are presented in a 
table format to give an accessible overview of the structures. The color-coding (blue for A ring 
substituents, red for C ring substituents) and substituent numbering (Figure 1) are retained in all 
structures throughout the review. A figure or table reference in bold indicates original research 
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describing synthetic preparation of a compound and in the tables, a substituent in italic signifies that it 
is modified compared to the parent compound. 
Several patents have been published regarding the properties of griseofulvin and its derivatives 
including synthesis, formulation and their medicinal and agricultural applications. The emphasis of this 
review is not on the patent literature and they will not be discussed further – references 
3,4,5,6,7,8,9,10,11,12,13,14 can be consulted for more information. 
 
2. The Discovery and Structural Analysis of Griseofulvin and Analogs 
Griseofulvin 1 was initially isolated from Penicillium griseofulvum in 1939 by Oxford et al.
15
 In 1946 
Brian et al. published studies of a compound isolated from P. janczewskii known as the "Curling 
Factor" due to its induction of curling of fungal hyphae.
16,17
 It was not until 1947 that it was established 
that griseofulvin 1 and the "Curling Factor" were in fact the same compound.
18,19
 The analogous 
metabolites dechlorogriseofulvin 2 (1953) and 7-bromo-7-dechloro-griseofulvin 3 (1954) were later 
isolated by MacMillan.
20,21
 
Initially, the structural analysis was performed by means of IR, UV spectroscopy and combustion 
analysis of derivatives or degradation compounds. The structure of the A-B-C ring system was first 
correctly assigned in 1951 by Grove et al.
22
 and in 1952, the stereochemistry of position 6’ was 
determined through identification of (R)-(+)-methylsuccinic acid as a degradation product of the C 
ring.
23
 The cis relation between the 3-oxo and 6’-methyl substituents was suggested in 1959 by 
MacMillan after studying the epimerization of the 2-position. He found that 2-epi-griseofulvin (22, 
Scheme 15) was the major product of the reaction and argued for the relative stereochemistry of 1 
 5 
 
based on steric repulsion between the 3-oxo and 6’-methyl moieties.24 The absolute configuration of 1 
was supported by X-ray crystallography of 5-bromogriseofulvin (87a, Scheme 18) in 1963 and by 
1
H 
NMR studies in 1971 before final confirmation via crystallography of griseofulvin by Malmros et al. in 
1977.
25,26,27
 The products of epimerization of either of the two stereogenic centers in griseofulvin, 
position 2 and 6', have throughout the literature been referred to as epi-griseofulvin and these 
compounds are of course identical in the racemic series. Much of the pioneering work on the chemistry 
of griseofulvin and its analogs was done in the 1950s and early 1960s by ICI and Glaxo and published 
in Journal of the Chemical Society in 17 papers called griseofulvin part I through XVII, by ICI 
Research Laboratories,
20,21,23,24,28,29,30,31,32,33,34,35,36,37,38,39,40
 and 9 papers called griseofulvin analogues 
part I through IX, by Glaxo Laboratories.
41,42,43,44,45,46,47,48,49
 
Several articles do not describe synthesis of griseofulvin 1 or analogs thereof, but instead report 
spectroscopic studies. Page and Staniforth investigated the infrared absorption of more than 180 
griseofulvin analogs.
45,48
 The IR spectra were recorded in bromoform and detailed absorption values 
are listed for all compounds. The authors were able to distinguish analogs of griseofulvin and 
isogriseofulvin as well as the position 2 epimers based on the IR data. A comprehensive mass 
spectrometry study of griseofulvin, its analogs and their fragmentation in the spectrometer was carried 
out by Ballantine and Fenwick.
50
 60 MHz 
1
H NMR was used in a study by Arison et al. covering 
griseofulvin and more than 25 analogs, exploring this, at the time, new technique.
51
 Another NMR 
study by Green et al. of more than 40 analogs concluded that the assignment of the 4 and 6 methoxy 
groups by Arison et al. was inaccurate.
49
 The assignment by Green et al. was confirmed by Rønnest et 
al. with 2D NMR and single crystal X-ray analysis of the position 4 and 6 norgriseofulvin analogs (80, 
Scheme 16 and 83, Scheme 17).
52
 The conformation and configuration of griseofulvin 1, the 4'-β-
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hydroxy analog (105, Scheme 24) and the 4’-α-methoxy analog (135c, Table 29) were determined by 
solution NMR (CDCl3) by Levine and Hicks and later they investigated the 
13
C NMR of griseofulvin 1, 
2-epi-griseofulvin 22 (Scheme 15), isogriseofulvin 79 (Scheme 14) and the analog 106 (Scheme 
24).
26,53,54
 NMR has also been used in studies of griseofulvin biosynthesis using deuterium labeling, for 
example in the work by Sato and Oda.
55
 
 
3. Biological Activity of Griseofulvin and Analogs of the Natural Product 
After the discovery of griseofulvin, many studies followed that reported the in vitro antifungal effects 
and systemic antifungal activity of 1 in plants.
56,57
 However, it was the report by Gentles in 1958 that 
griseofulvin was active against infections with Microsporum canis and Trichophyton mentagrophytes 
in guinea pigs when administrated orally and the work of Williams et al. published the same year on 
griseofulvin treatment of ringworm in man that sparked the development of griseofulvin as an 
antifungal drug to treat dermatophytosis in man.
58,59
 The early studies of griseofulvin as an antifungal 
agent have been reviewed by Bent and Moore and will therefore not be discussed further here.
60
 
A large number of analogs of griseofulvin have been prepared with the aim of improving the antifungal 
properties of the natural product. A few, notably 3’-benzyl-2’-demethoxy-2’-ethoxygriseofulvin (116o, 
Table 15), showed increased efficacy in vitro, but none of them have been introduced to the clinic. The 
specific biological activity of individual analogs is beyond the scope of this review and earlier reviews 
can be consulted for further information.
1,61
 Additionally, for all analogs reported here, references are 
given to biological studies where available (Tables 9-30). 
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The antifungal mode-of-action of griseofulvin has been the subject of considerable research efforts and 
some debate over the years, a discussion that is still ongoing. The action of griseofulvin has been linked 
to nucleic acid binding and it has also been shown that 1 interferes with mitosis through interaction 
with the mitotic machinery in a manner resembling colchicine.
62,63,64 
Furthermore, it has been 
demonstrated that griseofulvin binds to tubulin,
65
 inhibits tubulin polymerization and disturbs 
microtubule dynamics,
66
 but experiments indicate that the binding to tubulin has low affinity and often 
occurs at concentrations higher than the fungistatic effect. Taken in combination with studies in 
mammalian cells this has led to speculation that the cellular target of griseofulvin at clinically relevant 
concentrations might not be tubulin itself but rather a microtubule-associated protein.
67
  
The antimitotic and antiproliferative effect of griseofulvin in mammalian cells is weak, requiring high 
micromolar concentrations for a response.
68
 The interest in griseofulvin was renewed when Ho et al. 
reported in 2001 that griseofulvin could potentiate the antitumorigenesis effect of nocodazole and 
induce apoptosis in cancer cell lines at concentrations down to 1 µM.
69
 The report was preceded by a 
patent taken out on the application of griseofulvin for the treatment of cancer and viral infections and 
was followed by more detailed studies of the antimitotic effect of 1,
70
 confirming earlier findings of a 
tubulin polymerization inhibition at high doses and a lower-dose interference with microtubule 
dynamics.
71
 The ability of griseofulvin to suppress hepatitis C virus replication in vitro was reported by 
Jin et al. in 2008.
72
 In 2006 Oda published the cytotoxic effect of griseofulvin and three 2’ modified 
analogs in Chinese hamster V79 cells, finding that the 2’-demethoxy-2’-propoxy analog (115l, Table 
14) was the most potent, suggesting that the anticancer effect of 1 could be enhanced through structural 
modification of the natural product.
73
 The following year, Rebacz et al. helped shed additional light on 
the mode-of-action of griseofulvin and analogs in a report linking the spirobenzofuranones to inhibition 
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of centrosomal clustering, a functional mechanism in cancer cells to overcome the detrimental effects 
of supernumerary centrosomes and avoid multipolar mitosis during cell division.
74
 These findings were 
followed by an SAR study of 34 analogs of griseofulvin as centrosomal clustering inhibitors,
75
 as well 
as a detailed comparison between the antifungal and anticancer effect of 54 compounds showing a 
disparate SAR, indicating different modes-of-action in fungal and mammalian cells.
76
 For one of the 
most potent analogs, 2’-benzyloxy-2’-demethoxygriseofulvin (115aa, Table 14), a more detailed report 
was published including in vivo activity studies in murine xenograft models of colon cancer and 
multiple myeloma.
77
 
Griseofulvin and its analogs continue to attract attention for the multiple biological responses the 
molecules can elicit. Future research aimed at a more detailed understanding of the cellular targets of 
this compound class and the underlying binding interactions has the promise to increase the studies and 
potentially the pharmaceutical applications of 1 and its derivatives further. 
 
4. Fungal Biosynthesis of Griseofulvin 
Griseofulvin was one of the first antifungal natural products found in filamentous fungi.
18
 During the 
years, this polyketide has been found to be produced by several Ascomycetes including both closely and 
distantly related species. The majority of these are found in genus Penicillium, where at least sixteen 
species are known to be griseofulvin producers, whereas the production is seemingly rare in 
Aspergillus, as it has only been reported in A. lanosus.
78
 Griseofulvin production appears to be very 
consistent in all the species that have been examined systematically so far and the wide distribution of 
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griseofulvin among filamentous fungi indicates that the biosynthetic capability has been developed at 
least 13 independent times during evolution.
78
  
From the middle of the last century and onwards, huge efforts have been made to investigate the 
biosynthesis of natural products such as griseofulvin using isotope-labeled substrates. Based on the 
observations of incorporation of seven units of [1-
14
C]acetic acid into griseofulvin, Birch et al. in 1958 
supported the “acetic acid hypothesis”, suggesting that the core ring structure of many phenolic 
compounds were derived by head-to-tail linkage of acetic acid units.
79
 This theory was later revised as 
13
C NMR studies clarified that only the starter unit of the growing polyketide chain is derived from 
acetic acid, whereas the sequential chain extension resulting in the intermediate 6 (see Scheme 1), the 
precursor for the two first ring formations, uses six malonate units during extension of the polyketide 
chain.
80
 A phenoxyl radical cyclization mechanism for the formation of the core grisan ring of 
griseofulvin was suggested by Barton and Cohen in 1957.
81
 Rhodes et al. showed that methylated 
benzophenones are intermediates in griseofulvin biosynthesis in 1961,
82
 which was later clarified in 
1976 by Harris et al.,
83
 using isotope feeding experiments. The latter determined that O-methylation of 
two of the phenol groups occurs immediately after the formation of the benzophenone intermediate 8 
resulting in griseophenone C (9), whereas the last O-methylation takes place later in the biosynthetic 
pathway.  
 
In recent years, it has become possible and relatively inexpensive to sequence the full genomes of 
filamentous fungi. This has given complete new opportunities to study and understand the genomic 
basis and the enzymes involved in biosynthesis of polyketides such as griseofulvin. Initial efforts have 
 10 
 
been directed towards Aspergillus due to its medical and commercial importance;
84
 however, work has 
also been reported for other more exotic fungi including the investigation of griseofulvin’s biosynthesis 
in Penicillium aethiopicum.
85
 Analysis of the published sequenced genomes by different web-based 
tools, such as BLAST (Basic Local Alignment Search Tool), SMURF (Secondary Metabolite Unknown 
Regions Finder) and antiSMASH (antibiotics & Secondary Metabolite Analysis SHell) allows for 
prediction of putative polyketide synthase (PKS) genes based on sequence similarity to established 
genes from other species.
86,87,88,89
 For example A. nidulans has been predicted to have thirty two genes 
potentially involved in polyketide production.
90
 Moreover, these genes tend to be clustered together 
with tailoring and regulatory genes,
91
 making predictions of genes related to the same pathway possible 
as demonstrated recently by Andersen et al.
92
 The authors developed an algorithm for accurate 
prediction of secondary metabolite gene clusters in filamentous fungi based on analysis of 
transcriptome data, altogether setting the scene for linking genes to enzymatic activities for elucidation 
of secondary metabolic pathways, as well as heterologous expression of the proteins.
93
 
 
In 2010, Yi Tang’s group at UCLA located the genes involved in the biosynthesis of griseofulvin in 
Penicillium aethiopicum among seven non-reducing PKSs by genome scanning based on DNA 
pyrosequencing followed by comparative genomics to the closely related P. chrysogenum, which does 
not produce griseofulvin.
85
 Key to the identification of the griseofulvin gene cluster (Gsf) was the 
finding of three O-methyl-transferase encoding genes (Gsf B/C/D) and a halogenase gene (GsfI) 
pointing towards correlation to signature functional groups in griseofulvin (Scheme 1). Moreover, they 
found a P450 oxygenase (GsfF) responsible for the stereoselective formation of the B ring leading to 
the signature spiro structure and that stereoselective reduction in the C ring was mediated by the 
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putative NADP-dependent oxidoreductase GsfK resulting in formation of the C-6’ chiral center in the 
R-configuration. At the time, Chooi et al. proposed that chlorination by the halogenase GsfI was the 
final step in the biosynthesis of griseofulvin 1, which was in disagreement with previous feeding 
experiments performed by Harris et al.
83
  
 
Scheme 1. Proposed griseofulvin biosynthetic pathway adapted from Cacho et al. ACP is acyl carrier 
protein, NADPH is nicotinamide and SAM is S-adenosyl methionine.
94
 
In order to fully resolve the biosynthesis of griseofulvin, Yi Tang’s group followed their initial work in 
P. aethiopicum up with a comprehensive single-gene knock-out investigation leading to a complete 
assignment of the sequence of enzymatic events leading to biosynthesis of griseofulvin (1) using 
acetyl-CoA (4) as starter unit and six malonyl-CoA (5) as extender units (Scheme 1).
94
 Again the 
authors concluded that the intramolecular Claisen type reaction and aldol condensation of the 
heptaketide backbone 6 and 7, respectively, resulting in 8 proceeded despite neither a thioesterase nor a 
cyclase being part of GfsA, indicating that the PT domain promote both condensations. Deletion of 
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GsfB established that the initial methylation of 8 takes place at O-6 and that norlichexanthone (9) is 
formed as a shunt product, indicating that O-6 methylation resulting in griseophenone D (10) likely 
hinder dehydration and thereby suppress xanthone formation in wild type strains (Scheme 1). Similarly, 
deletion of the methyltransferase GsfC clarified that the second methylation takes place at 2’ before 
formation of the grisan ring in agreement with previous feeding studies.
82
 Deletion of the third 
methyltransferase encoding gene GsfD showed that C-7 chlorination takes place before methylation of 
O-4 since desmethyl-dehydrogriseofulvin (13) accumulated. C-7 chlorination was also demonstrated to 
take place prior to grisan ring formation since griseophenone B (12) accumulated in the GsfF knockout 
strain. Oxidation of the phenone ring in 12 forms the spirocyclic grisan compound 13 by a phenolic 
coupling catalyzed by the cytochrome P450 GsfF and the authors speculated that the mechanism could 
be either via a di-radical coupling or alternatively via an arene oxide intermediate.
94
 Finally, GsfE 
catalyze the stereospecific reduction of dehydrogriseofulvin (14) resulting in griseofulvin (1). 
 
5. Total Syntheses of Griseofulvin 
Several strategies have been utilized for the total synthesis of racemic griseofulvin, while the only 
enantioselective synthesis of the natural product (+)-griseofulvin 1 was published in 1991. The first 
total synthesis was completed in 1960 by Day et al. utilizing an oxidative cyclization of the 
benzophenone precursor 17 (Scheme 2),
95,96
 a strategy based on earlier pondering on the biosynthesis 
of 1.
81,97
 The two arenes 2-chloro-3,5-dimethoxyphenol 15 and 2-methoxy-4-((methoxycarbonyl)oxy)-
6-methylbenzoic acid 16 were coupled by converting 16 to the acid chloride with oxalyl chloride and 
Friedel-Crafts acylation of 15, which after saponification of the resulting carbonate afforded the phenol 
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17. The formation of the spiro center was completed by a radical reaction using potassium 
hexacyanoferrate(III) giving (±)-dehydrogriseofulvin 14. The final step was hydrogenation of 14 with a 
preformed 5 % rhodium on charcoal catalyst containing 3 % selenium yielding (±)-griseofulvin 1 in a 
very modest yield (17 was isolated as the major product in 70 % yield). Day et al. also demonstrated 
that chiral resolution of (±)-griseofulvic acid ((±)-78, Scheme 14) with N-methylquininium hydroxide 
was possible.
96
 
 
Scheme 2. Total synthesis of racemic griseofulvin by Day et al.  
 
Later in 1960 Brossi et al. (from the research division of Hoffmann-La Roche) formed the C ring of 
griseofulvin via a Dieckmann cyclization (Scheme 3).
98,99
 The synthesis of the substituted 
benzofuranone 20 started with 18, which when treated with potassium carbonate and methyl 2-
bromoacetate gave 19, that was ring-closed with a Dieckmann cyclization yielding 20. Michael 
addition of the benzofuranone 20 to 3-penten-2-one resulted in 21 with two diastereoisomeric products 
formed, where the major product was used for a second Dieckmann cyclization after which methylation 
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with diazomethane afforded (±)-epi-griseofulvin 22. Epimerization with sodium methoxide yielded (±)-
griseofulvin 1. Brossi et al. also demonstrated that chiral resolution of (±)-griseofulvic acid ((±)-78, 
Scheme 14) with brucine was possible.
98
 
 
Scheme 3. Total synthesis of racemic griseofulvin by Brossi et al.  
 
At the end of 1960 Kuo et al. (from the Merck Sharp & Dohme Research Laboratories) described a 
different synthetic route to the benzophenone 17 (Scheme 4).
100
 When performing a Friedel-Crafts 
acylation with 15 and 23 they obtained 24. Irradiation of 24 gave 17 in a modest yield, which again was 
cyclized with alkaline potassium hexacyanoferrate(III) giving 14. The reduction with hydrogen and 
palladium on charcoal yielding (±)-griseofulvin 1 was improved giving a much higher yield compared 
to the conditions used by Day et al. 
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Scheme 4. Total synthesis of racemic griseofulvin by Kuo et al. 
 
In 1962 Brossi et al. showed that chiral resolution of epi-griseofulvic acid (69b, Table 7) with 
enantiomerically pure 1-phenylethylamine was possible.
101
 Also in 1962 Stork and Tomasz reported a 
one-pot synthesis using a double Michael addition to establish both stereocenters and the 2'-enol ether 
(Scheme 5).
102,103
 The key substrate in the synthesis was the methoxyethynyl vinyl ketone 26, which 
when reacted with benzofuranone 25 in the presence of potassium tert-butoxide gave racemic 1. 
 
 
Scheme 5. Total synthesis racemic griseofulvin by Stork and Tomasz. 
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In 1962 Taub et al. modified the method described by Day et al. First 7-dechloro-7-fluoro-griseofulvin 
(63p, Table 1) was prepared followed by 6'-desmethyl-griseofulvin (64g, Table 2) and several 
chlorinated analogs, before publishing the optimized synthetic route to griseofulvin 1, Scheme 
6.
104,105,106,107
 In the 2
nd
 article from 1962 published in Chemistry and Industry, introduction of the 
chloro substituent was the final step.
106
 The optimized total synthesis prepared the benzophenone 17 
from two aromatic precursors similar to Day et al.
95,96,107
 The arene 27 destined to become the C ring 
differed as the phenol was acetyl protected and the carboxylic acid was used instead of an acid 
chloride. The coupling was performed in trifluoroacetic anhydride resulting in benzophenone 28. 
Reaction of the intermediate mixed trifluoroacetic anhydride of 27 (not illustrated in Scheme 6) with 
the phenol functionality in 15 was a major by-product, however, it could be converted into 17 by 
hydrolysis of the acetyl ester followed by a Fries rearrangement with titanium tetrachloride increasing 
the total yield of 17 from 50 % to 65 %. Ring closure of 17 to (±)-dehydrogriseofulvin 14 (not 
illustrated in Scheme 6) was achieved using several methods and quantitative yields were obtained 
using potassium hexacyanoferrate(III), lead dioxide or manganese dioxide. Hydrogenation to (±)-1 was 
performed in ethyl acetate using pre-reduced 10 % palladium on charcoal as the reductant. Taub et al. 
also demonstrated that chiral resolution of (±)-griseofulvic acid ((±)-78, Scheme 14) with N-
methylcinchonium hydroxide was possible.
107
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Scheme 6. Total synthesis by Taub et al. 
 
In 1979 Danishefsky and Walker reported a total synthesis of 1 using a Diels-Alder cycloaddition 
strategy (Scheme 7), the synthesis was based on the total synthesis of (±)-epi-griseofulvin by 
Danishefsky and Etheredge.
108,109
 The dienophile 31 was synthesized from 29 through double 
intramolecular nucleophilic attack giving 30, followed by substitution with a thiophenol and oxidation 
with m-chloroperoxybenzoic acid to the sulfoxide 31. The dienophile 31 reacted with the diene 32 in 
toluene at 100-135 °C yielding (±)-dehydrogriseofulvin 14, which analogous to Taub et al. was 
hydrogenated with pre-reduced palladium on charcoal to (±)-griseofulvin 1. 
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Scheme 7. Total synthesis by Danishefsky et al. 
 
In 1990, an improvement of the method by Stork and Thomas using a double Michael addition was 
published by Yamato et al. Scheme 8).
110
 The benzofuranone 25 was reacted with the Michael acceptor 
33 giving 34 and treatment with activated alumina resulted in (±)-2'-demethoxy-2'-methylthio-
griseofulvin 35. Substitution of the thioether was achieved by oxidizing sulfur with m-
chloroperoxybenzoic acid and reaction with sodium methoxide resulted in (±)-griseofulvin 1. 
 
Scheme 8. Total synthesis by Yamato et al. 
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In 1991 Pirrung et al. reported the first and only total synthesis of enantiomerically pure (+)-
griseofulvin 1 (Scheme 9).
111
 The phenol 36 was used as the nucleophile in a Mitsunobu coupling with 
37 giving the triether 38. Reacting 38 with Mander's reagent followed by a diazo transfer reaction 
resulted in 39. Treatment of 39 with 5 % rhodium pivalate catalyst yielded, through a sigmatropic 
rearrangement, the benzofuranone 40, which was converted by ozonolysis to an aldehyde that 
underwent a Wittig reaction. TFA cleaved the tert-butyl ester, the carboxylic acid was converted to an 
acyl azide, Curtius rearrangement followed by hydrolysis of the resulting enamide gave 41. The keto 
ester 41 was cyclized by a Dieckmann cyclization and finally, diazomethane methylation completed the 
first total synthesis of (+)-griseofulvin 1. 
 
 
Scheme 9. Enantioselective total synthesis of griseofulvin by Pirrung et al. 
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6. De Novo Syntheses of Analogs 
Some A ring analogs of griseofulvin can be prepared directly from the natural product (vide infra), 
whereas B ring and position 6’ modifications are not possible by this strategy. Consequently, several A 
ring analogs and all B ring and position 6’ analogs have been prepared by strategies developed for the 
total synthesis of 1. The strategies used were oxidative cyclisation, Diels-Alder, double Michael 
addition, Dieckmann cyclization and the improved Michael strategy.
109,112,113,114,115,116,117,118,119,120,121,122
 
In 1980, a total synthesis of a 5-methylated 6’ modified dehydrogriseofulvin 43 was completed by 
Sargent (Scheme 10).
123
 Treatment of the precursor 42 with hydrogen chloride and titanium 
tetrachloride in dichloromethane yielded 43 through an intramolecular ipso-acylation. 
 
 
 
Scheme 10. Analog synthesis by Sargent. 
 
6.1 Analogs with a Modified B Ring 
Newman and Angier developed a novel strategy for the preparation of the B ring analogs, with a 
Hoesch condensation as the ring forming step (Scheme 11).
124
 In the first step a cyano group was 
introduced by condensation of 44 with ethyl cyanoacetate using piperidine in a catalytic amount, which 
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after hydrogenation with 10 % palladium on charcoal gave the nitrile 45. The nitrile was reacted further 
with the Michael acceptor but-3-en-2-one using sodium methoxide yielding crude 46. A Dieckmann 
condensation with methoxide in methanol resulted in 47 with the C ring formed and the following 
Hoesch condensation with hydrogen chloride and zinc chloride in diethyl ether gave the position 1 
carbon analog of 7-dechloro-6’-desmethylgriseofulvic acid 48. 
 
 
Scheme 11. Synthesis of 48 by Newman et al.
124
 
 
An alternative strategy had to be developed for the 6’-methyl derivative 52a (Scheme 12) as the 
Hoesch condensation of its cyano precursor gave a non-spiro product.
125
 The keto-ester 50 was coupled 
to 49a with sodium ethoxide in ethanol followed by acetal hydrolysis to give 51a. The ester was 
hydrolyzed and treatment with trifluoroacetic anhydride and boron trifluoride etherate gave the desired 
product 52a.
125
 This modified strategy was used to prepare the griseofulvic acid derivative 52b and its 
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corresponding griseofulvin and isogriseofulvin analogs 53 and 54 by methylation with 
diazomethane.
126
 
 
 
Scheme 12. Total synthesis of the 1-carbon analogs 52, 53 and 54 by Newman and Angier.
125,126
 
 
Newman and Angier also prepared 1-thio-epi griseofulvin analogs using the route illustrated in Scheme 
13.
127
 The thiophenol 55 was coupled with 56 using sodium carbonate affording 57. The crude product 
was debrominated with potassium iodide in aqueous acetic acid yielding 58, which was methylated 
with diazomethane in diethyl ether giving a mixture of 59 and 60. Treatment of the 59/60 mixture with 
methanolic sodium methoxide gave 61. Chlorination with sulfuryl chloride provided a mixture of R
5
 
and R
7
 chlorinated epi-analogs 62. 
 
 23 
 
 
Scheme 13. Total synthesis of the 1-thio analogs 61 and 62 by Newman and Angier.
127
  
In 2013, Dong et al. employed an asymmetric Michael-aldol tandem reaction to synthesize 2’-phenyl, 
6’-epi modified analogs.128 Different chiral 1,2-diamine catalysts were tested in the reaction and the 
best enantioselectivity was achieved when using 9-aminocinchonine. 
 
6.2 Tables of Griseofulvin Analogs Prepared by de Novo Synthesis 
The analogs synthesized by means of de novo synthesis are given in Tables 1-8 and Figure 2 and all 
compounds illustrated are racemic mixtures, if no relative stereochemistry is indicated it was not 
reported in the original literature. The analogs are sorted in classes based on their C ring similarity. 
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Table 1. Position 4, 5, 6, 7 and 2’ modifications of griseofulvin. 
Structure  R4 R5 R6 R7 R2’ Reference 
63a H H  H H  OMe  112 
63b H H  H H  OEt  112 
63c H H  H Cl  OMe  112 
63d H H  H Cl  OEt  112 
63e H H  OMe Cl OMe 113 
63f H H OMe  Cl SMe 113 
63g H H Cl H OEt 112 
63h H Me H Cl OEt 112 
63i H  OMe  H  Cl OMe 113 
63j H  OMe  H  Cl SMe 113 
63k H Cl  H H  OEt  112 
63l OMe  H  H  Cl OMe 113 
63m OMe  H  H  Cl SMe 113 
(±)-2 OMe H OMe H OMe 104,106,114,115 
63n OMe H  OMe  Me  OMe  115a 
63o OMe  H  OMe  NO2  OMe  115 
63p OMe  H  OMe  F  OMe  104,116 
63q OMe  H  OMe  Cl  OEt  112 
(±)-35 OMe H OMe Cl SMe 110,117 
63r OMe H OMe I OMe 115 
63s OMe  Me  OMe  Cl OMe 113 
63t OMe  Me  OMe  Cl SMe 113 
63u OMe CO2Et  OMe  Cl OMe 118 
63v OMe  NO2  OMe  H  OMe  115 
63w OMe  OMe  OMe  Cl OMe 113 
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63x OMe  OMe  OMe  Cl SMe 113 
63y OMe  Cl  OMe  H  OMe  104,106,114,115 
63z OMe  Cl  OMe  Cl OMe 106,113 
63aa  OMe  Cl  OMe  Cl SMe 113 
a
 Mixture of epi-analogs. 
 
 
Table 2. Position 5, 7, 2’ and 6’ modifications of griseofulvin. 
Structure R5 R7 R2’ R6’ (α) R6’ (β) Reference 
64a H H Me H H 119 
64b H H OMe H H 115 
64c H H OMe H Et 120 
64d H H OMe Et H 120 
64e H NO2 OMe H H 115 
64f H Me OMe H H 115 
64g H Cl  OMe H  H  105,114,120,121 
64h H Cl  OMe H  Et  117,120 
64i H Cl  OMe H Ph 117 
64j H Cl  OMe Me  Me  121 
64k H Cl  OMe Et H  120,121 
64l H Cl SMe H Et 117 
64m H Cl SMe H Ph 117 
64n H Cl SEt H Et 117 
64o H Cl SEt H Ph 117 
64p NO2 H OMe H H 115 
64q Cl H OMe H H 115 
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Table 3. Position 5, 7 and 2’ modifications of epi-griseofulvin. 
Structure R5 R7 R2’ Reference 
65a H H OMe 115 
65b H Me OMe 115a 
(±)-22 H Cl OMe 99,109,117,121 
65c H Cl OEt 112 
65d H Cl O(CH2)2OMe 112 
65e H Cl SMe 117 
65f H I OMe 115 
65g Cl H OMe 115 
a
 Mixture of epi-analogs. 
 
6.3 Tables of Isogriseofulvin Analogs Prepared by de Novo Synthesis  
 
 
Table 4. Position 5, 6, 7, 4’ and 6’ modifications of isogriseofulvin. 
Structure R5 R6 R7 R4’ R6’ Reference 
66a H OMe H OMe H 115 
66b H OMe Cl OMe H 115 
66c H OMe Cl OMe Et 117 
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66d H OMe Cl OMe Ph 117 
66e H OMe Cl OEt Me 112 
66f H OMe Cl SEt Et 117 
66g H OMe Cl SEt Ph 117 
66h Cl OMe H OMe H 115 
 
 
Table 5. Position 5, 7 and 4’modifications of epi-isogriseofulvin. 
Structure R5 R7 R4’ Reference 
67a H H OMe 115 
67b H Me OMe 115 
67c H Cl OMe 99 
67d Cl H OMe 115 
 
6.4 Tables of Griseofulvic acid Analogs Prepared by de Novo Synthesis  
 
 
Table 6. Position 5 and 7 modifications of 6’-desmethylgriseofulvic acid. 
Structure R5 R7 Reference 
68a H H 115 
68b H Me 115 
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68c H Cl 115 
68d Cl H 115 
 
 
 
Table 7. Position 5 and 7 modifications of epi-griseofulvic acid. 
Structure R5 R7 Reference 
69a H H 115 
69b H Cl 99 
69c H I 115 
69d H Me 115 
69e Cl H 115 
 
6.5 Miscellaneous Analogs Prepared by de Novo Synthesis 
 
 
Table 8. Position 4, 5, 7 and 6’ modifications of dehydrogriseofulvin. 
Structure R4 R5 R7 R6’ Reference 
70a Me H H Me 123 
 29 
 
70b OMe H H Me 106,114 
70c OMe H F Me 104,116 
70d OMe H Cl H 105,114 
(±)-14 OMe H Cl Me 95,96,97,98,99,107 
70e OMe Cl H Me 106,114 
 
 
Figure 2. Structures of miscellaneous analogs prepared by de novo synthesis 71 (ref. 106, note: 
inconsistent data regarding stereochemistry), 72 (ref. 120), 73 (ref. 120), 74 (ref. 120), 75 (ref. 112), 76 
(ref. 112) and 77 (ref. 122). 
7. Synthetic Griseofulvin Analogs 
Numerous analogs of (+)-griseofulvin 1 have been synthesized, common for all is their syntheses from 
enantiomerically pure 1, which generally resulted in single antipodes. 
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Scheme 14. Conversion between griseofulvin 1, griseofulvic acid 78 (drawn as the predominant 
tautomer in solution) and isogriseofulvin 79. 
 
Analogs of griseofulvin are sorted into four major classes primarily depending on the substitution on 
the C ring. The three first consist of griseofulvin 1, griseofulvic acid 78 and isogriseofulvin 79 analogs, 
after which comes a section describing the remaining analogs. In Scheme 14 the three compounds and 
the interconversion between them are given. Griseofulvin 1 can be hydrolyzed with dilute aqueous 
sulfuric acid yielding 78, which can be converted into griseofulvin 1 and isogriseofulvin 79 with 
diazomethane in diethyl ether or more selectively into isogriseofulvin 79 with acid-catalyzed 
methanolysis based on the findings by Duncanson et al.
37,41
 Brossi et al. found that (±)-79 can be 
hydrolyzed to (±)-78 by 0.1 M sodium carbonate in 1,4-dioxane.
99
 If more alkaline conditions are used 
epimerization of the spiro center in griseofulvin 1 (Scheme 15) occurs, e.g. by refluxing 1 in 
methanolic sodium methoxide as described by Mulholland et al.
24
 Two epimerization mechanisms were 
initially suggested by MacMillan et al. and the one illustrated in Scheme 15 was later supported by 
Brossi et al.
24,99
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Scheme 15. Epimerization of 1 into 22 and the suggested mechanism for the reaction. 
 
Some of the earlier A ring modifications were made by MacMillan et al. in the late 1950s to determine 
the absolute structure, stability and reaction of griseofulvin 1 and some of its derivatives upon 
treatment with various reagents and under different conditions.
24,36
  
In 1962, Arkley et al. showed that griseofulvin 1 could be selectively demethylated in the 4 position 
with magnesium iodide giving 80 followed by O-4 alkylation with various alkylating reagents using 
either potassium carbonate or silver oxide resulting in 81 (Scheme 16).
41
 The 5-allyl modified 
griseofulvin 82 was synthesized from the 4-O-allyl derivative of 81 by a Claisen rearrangement 
(Scheme 16) and Arkley et al. also showed that position 6 modified griseofulvin compounds could be 
synthesized from griseofulvic acid 78 by position 6 demethylation followed by position 4’ methylation 
resulting in the 6-desmethyl isogriseofulvin analog 83, which was subsequently alkylated and 
converted to griseofulvin analogs of the general structure84 by hydrolysis. The griseofulvic acid 
derivatives could be converted into the griseofulvin analogs (Scheme 17, conversion not illustrated).
41  
 32 
 
 
 
Scheme 16. Position 4 demethylation and a typical position 4 alkylation, followed by Claisen 
rearrangement of the 4-allyloxy analog. 
 
 
Scheme 17. Position 6 demethylation of griseofulvic acid 78 followed by silver oxide mediated 
alkylation of the phenol.
41
  
 
Later in 1962, Walker et al. determined that position 5 chlorination could be made via griseofulvic acid 
with chlorine in carbon tetrachloride resulting in the 3’,3’,5-trichloride 85. The trichloride was 
selectively 3’-dehalogenated using potassium iodide resulting in the griseofulvic acid analog 86 
followed by alkylation of O-2’/O-4’ with either diazo alkyls or alkyl halides giving mixtures of 
halogenated griseofulvin and isogriseofulvin analogs (Scheme 18, alkylation not illustrated).
43
 Position 
3’ was the initial halogenation site on griseofulvic acid 78 with either chlorine in carbon tetrachloride 
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or bromine and iodine respectively in DMF.
43
 Bromination of the 5 position could be done directly on 
griseofulvin 1 with bromine and mercury(II) acetate yielding 87a (Scheme 18).
43
 In 1972 Barton et al. 
discovered direct fluorination of griseofulvin 1 with trifluoromethyl hypofluorite, which yielded 5-
fluorogriseofulvin 87b as the major product and 3’-fluoro (10 %) and 3’,5-difluorogriseofulvin (10 %) 
as minor products (Scheme 18), while Rønnest et al. in 2009 showed that direct 3’-iodination of 
griseofulvin could be performed with N-iodosuccinimide and triethylsilyl trifluoromethanesulfonate in 
dichloromethane resulting in 3’-iodogriseofulvin (116m, Table 15).75,129 
 
Scheme 18. Typical halogenation with chlorine in carbon tetrachloride and de-chlorination of 
griseofulvic acid 78 or position 5 bromination/fluorination of griseofulvin 1 with bromine or the 
fluorination reagent trifluoromethyl hypofluorite, respectively.
43,129
 
 
In 1963 Arkley et al. demonstrated that nitration of griseofulvin 1 in the 5 position affording 88 was 
possible as well as nitration in position 7 giving 90 when starting from 7-dechloro griseofulvin 2.
46
 
Arkley et al. also demonstrated that the nitro functionality could be reduced with iron in acetic acid 
yielding the 5-amino analog 89 (Scheme 19).
46
 MacMillan had originally discovered that de-
chlorination of position 7 occurred during reduction of griseofulvin 1 with hydrogen in the presence of 
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palladium on charcoal, with concomitant reduction of the C ring alkene.
31
 Arkley et al. discovered that 
griseofulvic acid 78 should be used as the precursor for 7-dechlorogriseofulvin 2 (Scheme 19).
46
  
 
 
Scheme 19. Nitration reactions and the position 7 de-chlorination from griseofulvic acid (78).
46
 
 
Duncanson et al. showed in 1958 that mixtures of 2’-griseofulvin analogs 91 and 4’-isogriseofulvin 
analogs 92 could be prepared by alkylation of griseofulvic acid 78 with either diazo alkyls or acid-
catalyzed alcoholysis of griseofulvin 1 with varying yields.
37
 In 1962 Gregory et al. employed base 
mediated 3’-alkylation of griseofulvic acid followed by conversion into mixtures of the griseofulvin 
and isogriseofulvin analogs similar to the route for 3’ halogenated analogs.42 Later in 1962 a more 
selective 2’ substitution method using a 2’-chloro precursor 93 was developed (Scheme 20).44 
Griseofulvic acid 78 was treated with moist phosphoryl chloride and lithium chloride giving a mixture 
of 93 and 94 and after separation, the respective chloro-compounds were treated with different 
nitrogen-, oxygen- and sulfur-based nucleophiles resulting in analogs of griseofulvin 91 and 
isogriseofulvin 92, respectively.
44,47,75,76
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Scheme 20. Typical examples of conditions for synthesizing 2’- and 4’-analogs of griseofulvin 91 and 
isogriseofulvin 92 (R ≠ Me) prepared by: a) alcoholysis of griseofulvin 1 or griseofulvic acid 78; b) 
alkylation of griseofulvic acid 78 with diazoalkyls or c) chlorination of griseofulvic acid’s C ring at the 
2’ or 4’ positions (93 and 94, 99 % conversion) and d) nucleophilic conjugate addition and chloride 
elimination illustrated with ROH.
 37,44,47,75,76 
 
Nitrogen-containing 4’-griseofulvin analogs, illustrated with the 4’-oxime analog 95, were prepared by 
treating the 4’-oxo precursor with the relevant azane using suitable conditions, 75,76,130,131 while the 
sulfur analogs, illustrated with the dimethyl dithioacetal analog 96, were prepared from 1, the 
corresponding thiol and p-TSA (Scheme 21).
132
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Scheme 21. 4’-Analogs prepared from griseofulvin 1. 
 
In 1970, Newman and Fields treated griseofulvin with methyl formate and sodium methoxide and 
accomplished 5’-formylation in high yield (97).133 Together with Angier they later showed that the 5’-
formyl derivative could be converted to the 5’-diazo analog 98 using p-tosyl azide and diethyl amine in 
dichloromethane and the 5’-diazo analog could be reacted further illustrated with thioacetic acid in 
Scheme 22.
134
 The two 5’ modified griseofulvin analogs 97 and 98 have been the precursors for many 
of the 5’-derivatives described in the literature.133,134,135 Stereoselective 5’ hydroxylation by 
fermentation with Streptomyces Cinereocrocatus was done on gram scale by Andres et al.
136
 By 
treating 5’-formylgriseofulvin 97 with hydrazine Newman et al. synthesized the new tetracyclic analog 
100 and when reacting 97 with hydroxyl amine followed by acetic acid, an isoxazole analog 102 was 
prepared (Scheme 22).
135
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Scheme 22. Synthesis of the 5’-formyl analog 97 and conversion of the 5’-formyl analog into the 5’-
diazo analog 98, its derivatization and synthesis of two tetracyclic compounds from 97.
133,134,135
  
 
In 1952, Mulholland prepared additional analogs by hydrogenation of griseofulvin (and 
isogriseofulvin) with either palladium or platinum on charcoal.
31
 In Scheme 23, some of the products 
(72, 73, 103 and 104) from griseofulvin reduction with palladium on charcoal and hydrogen gas are 
illustrated. Mulholland later used reductions and oxidations to prepare a variety of different analogs.
32
 
In 1960 Kyburz et al. used sodium borohydride to reduce the 4’-oxo functionality of griseofulvin 
yielding the hydroxy analog 105 and 2’-oxo functionality in isogriseofulvin, the reduced hydroxy 
compounds were used as precursors for further analogs illustrated by compound 106 (Scheme 24).
137
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Scheme 23. Typical products from hydrogen reductions of griseofulvin 1 in ethyl acetate with 10 % 
palladium on charcoal.
31
 
 
 
Scheme 24. Sodium borohydride reduction of griseofulvin’s 4’-oxo functionality and hydrolysis-
elimination to form the analog 106.
137
 
 
In 1970, Newman showed that treatment of griseofulvin 1 with alkaline hydrogen peroxide afforded 2’-
3’-epoxidation (the use of benzoyl peroxide resulted in lower yields) giving the oxirane analog 107 and 
in 1971 published that treatment of 1 with sodium dimethylsulfoxide methylide resulted in the analog 
108 where 2’-3’-cyclopropanation and 4’-methylene transfer / epoxidation of griseofulvin 1 had 
occurred (Scheme 25).
138,139
 Newman proceeded to synthesize two new cyclopropyl analogs 109 when 
treating 108 with methanolic sodium methoxide or dimethylamine in methanol. 
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Scheme 25. Synthesis of the oxirane and cyclopropyl analogs by Newman.
138,139
 
  
7.1 Tables of Griseofulvin Analogs 
In the cases where the relative stereochemistry is not indicated for compounds in tables 9-30 and Figure 
3, it was not reported in the original literature. The analogs are mainly sorted in classes depending on 
their C ring similarity. 
 
 
Table 9. Position 4 modifications of griseofulvin. 
Structure R4 Reference 
110a Me  47,49,50 
110b 1-Pyrrolidinyl 47,49,50 
80 OH  41,52,75,76 
110c OEt  41,45,49,75,76 
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110d OPr  41,45 
110e OBu  41,45,61  
110f Opentyl 76 
110g Ocitronellyl 140,141 
110h O(CH2)2NMe2 41 
110i O(CH2)2NEt2 41 
110j O(CH2)2-1-pyrrolidinyl 41 
110k O(CH2)2-1-piperidinyl 41 
110l O(CH2)2N
+(Me)2(Et) Br
- 41 
110m OAll  41,45,61,142,143 
110n OBn  41,45,61,75,76,142,143  
110o OCH2-(4-methoxyC6H4) 140,141 
110p OCH2-(3-diethylcarbamoylC6H4) 140,141 
110q OCH2-1-naphtyl 76 
110r OCH2CONH(CH2)2NEt2 41 
110s OCH2CONH(CH2)3NEt2 41 
110t OCH2CONHBn  41 
110u OCH2CONHPh  41 
110v OCH2CONH-(4-chloroC6H4) 41 
110w OCH2CO2H 41 
110x OCH2CO2Me 41 
110y OCH2CO2Bn 41 
110z O-i-Pr  41,45,49 
110aa OCH(Me)CH2NMe2 41 
110ab OAc  41,49 
110ab OSO2Me 50 
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Table 10. Position 5 modifications of griseofulvin. 
Structure R5 Reference 
111a Pr  41,45,49 
82 All 41,45  
89 NH2 46,75,76,130 
111b NHBn  75 
88 NO2 46,75,76,130,144 
87b F 129 
111c Cl  43,45,49,50,51 
87a Br  43,45,144 
 
 
 
Table 11. Position 6 modifications of griseofulvin. 
Structure R6 Reference 
112a 1-Pyrrolidinyl 47,49 
112b OH  41,50,52,76,145 
112c OEt  41,45,49,61,76,142,143 
112d OPr  41,45,61,142,143 
112e OBu  41,45 
112f Ohexadecyl 41,45  
112g OBn  41,45  
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112h OCH2CO2Me 41 
112i O-i-Pr  41,45,49,61 
112j OAll 41,45,61,142,143 
112k OAc  41,49 
 
 
 
 
Table 12. Position 4, 5, 6 and 7 modifications of griseofulvin. 
Structure R4 R5 R6 R7 Reference 
113a OH  OH  OMe  Cl 146 
113b OH  NO2  OH  Cl  46 
2 OMe H MeO H 35,45,46,49,50,51a,147,148, 149 
113c OMe H  OMe F  51,116 
90 OMe H  OMe NH2 46,50 
113d OMe H  OMe NO2 46 
113e OMe H OMe N2
+ BF4
- 46 
113f OMe NH2  OMe H  46,50 
113g OMe NHBz  OMe H  46 
113h OMe NO2  OMe H  46 
113i OMe  OH  OH  Cl 146 
63y OMe Cl  OMe H  51 
113j OMe Cl  OMe Cl 114 
113k OEt  H OEt  Cl 24,45 
113l SMe  H SMe  Cl 47,49 
a
 Racemic mixture 
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Table 13 Position 4, 5, 6, 2’, 3’ and 5’ modifications of griseofulvin. 
Structure R4 R5 R6 R2’ R3’ R5’ Reference 
114a 1-Pyrrolidinyl H OMe  1-Pyrrolidinyl H H 47 
114b OH Br OMe OMe Br H 43 
114c OMe  H 1-Pyrrolidinyl 1-Pyrrolidinyl H H 47 
114d OMe H OMe H H Br 159 
114e OMe H OMe H Br H 159 
114f OMe H OMe CH2Br H Br 150
a 
114g OMe  H OEt  OEt  H H 36,45,49,147,149 
114h OMe H OBu OBu H H 41,45 
114i OMe F OMe OMe F H 129 
114j OMe Cl OMe OMe H Cl 114 
114k OMe Cl  OMe OMe Cl  H 43,45,49,51,114 
114l OMe Br OMe OMe Br H 43 
114m OEt  H OEt  OEt  H H 24,45,49 
a
 R
5’α
 configuration 
 
 
Table 14. Position 2’ modifications of griseofulvin. 
Structure  R2’ Reference 
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115a H  32,45,48,49,50,73,147,148,151,159 
115b Me  150 
115c CH2Br 150 
115d NH2 28,47,48,147,148,149,152 
115e NHMe  47,48,49,152 
115f NHEt  47,48 
115g NH(CH2)3NMe2, HCl 44 
115h NH(CH2)3NEt2, HCl 44 
115i NH(CH2)2NEt2 44,48 
115j 1-Pyrrolidinyl 47,48,49,50 
115k OEt  24,42,44,45,49,51,61,75,76,142,143,147,148  
115l OPr  37,45,61,73,75,76,142,143,147,149 
115m OBu  37,45,61,75,142,143,147,149 
115n Opentyl  37,75  
115o Ohexyl  37,45,61,75  
115p Oheptyl 37 
115q Ooctyl 37 
115r Odecyl 37 
115s Opentadecyl 37 
115t O(CH2)2Ph  75,76 
115u O(CH2)2Br  153 
115v O(CH2)2
125I  153 
115w O-i-Bu 37 
115x OCH2-cyclo-Pr  75,76  
115y OAll 42,45,61,142,143 
115z OCH2-1-adamantyl 75,76  
115aa OBn  42,45,61,75,76,142,143 
115ab OCH2-(4-methylC6H4)  75,76  
115ac OCH2-4-biphenyl  75,76  
115ad OCH2-(4-trifluoromethylC6H4) 76 
115ae OCH2-(4-hydroxymethylC6H4) 76 
115af OCH2-(4-methoxyC6H4) 76 
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115ag OCH2-(3-methoxyC6H4) 76 
115ah OCH2-(2-methoxyC6H4) 76 
115ai OCH2-(4-fluoroC6H4) 76 
115aj OCH2-1-naphtyl 76 
115ak OCH2-4-pyridyl 76 
115al OCH2-3-pyridyl 76 
115am OCH2-2-pyridyl 76 
115an O-i-Pr  41,45,75,76 
115ao O-cyclo-pentyl  75,76  
115ap Tetra-O-acetyl-α-D-glucosyloxy 37a,147 
115aq OPh  45,61,75,76,142,143 
115ar SMe  44,45,48,49,50,61,132 
115as SEt  44,45,61,117,132 
115at SPr  44,45,61,132 
115au SBu  44,45,61,132 
115av S(CH2)2NEt2 44 
115aw S(CH2)2-N-phthalimidyl 44 
115ax S(CH2)2OH  44 
115ay SAll 44,45,61 
115az SBn  44,45,61,75,76 
115ba S-i-Pr  132 
115bb SPh  44,61 
115bc S-2-imidazolyl 44 
93 Cl  44,45,48,49,50,75 
a
 Not fully characterized – could be the 4’-substituted isogriseofulvin  
 
 
Table 15. Position 2’ and 3’ modifications of griseofulvin. 
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Structure  R2’ R3’ Reference 
116a OMe  NHAc  46 
116b OMe  NHBz 46 
116c OMe NC(OMe)Ph 46 
116d OMe  NO2 46 
116e OMe  Me  42,45,49,50,61,142,143,152 
116f OMe  Pr  42,45,61,142,143,152 
116g OMe  (CH2)2C(O)Me 42 
116h OMe  All 42,45,61,142,143  
116i OMe  Bn  42,45,61,142,143,152 
116j OMe  F  129 
116k OMe  Cl  43,45,49,51,61,142,143,152 
116l OMe  Br  43,45,61,142,143 
116m OMe  I  43,45,61,75,76,142,143 
116n OEt  Et  42,45,61,142,143  
116o OEt  Bn  42,45,61,142,143  
116p OEt  Cl  43,45,61,142,143  
116q OEt  Br  43,45,61,142,143  
116r OEt  I  43,45,61,142,143  
116s OPr  Pr  42,45,61,142,143 
116t OPr  Bn  42,45,61,142,143  
116u OPr  Cl  43,45,61  
116v OPr  Br  43,45,61,142,143 
116w OPr  I  43,45,61,75,76,142,143 
116x OBu  Bn  42,45,61,142,143 
116y OBu  Cl  43,45,61 
116z OBu  Br  43,45,61 
116aa OBu  I  43,45,61 
116ab O(CH2)3Br  Bn  42 
116ac OBn  Cl 43,61 
116ad OBn  Br 43 
116ae OBn  I  43,75,76  
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116af OPh Cl 44 
116ag SMe  Pr  44,45 
116ah SMe  Bn  44,45,61 
116ai SMe  Cl 44,45,61 
116aj SMe  Br 44,45 
116ak SEt  Bn  44,45,61 
116al SEt  Cl  44,45,61 
116am SPr  Pr  44,45,61 
116an SPr  Bn  44,45,61 
116ao SPr  Cl  44,45,61 
116ap SPr Br 61 
116aq SBu  Pr  44,45 
116ar SBu  Bn  44,45 
116as SBu  Cl  44,45 
116at SAll Pr  44,45 
116au SAll Bn  44,45,61 
116av SAll Cl  44,45,61 
116aw SBn  Pr  44,45 
116ax SBn  Bn  44,45 
116ay SBn  Cl  44,45 
116az Cl  Pr  44,45 
116ba Cl  Bn  44,45 
116bb Cl  Cl  44,45 
116bc Cl  Br  45 
 
 
 
Table 16. Position 2’ and 4’ modifications of griseofulvin. 
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Structure R2’ R4’ R4’ Reference 
117a OMe =NNMe2 75
a 
117b OMe =NNHS(O)NH2 131 
95 OMe  =NOH 75,76,130,154,155 
117c OMe  =NOCH2CO2H 154 
117d OBn =NOH 75,76  
117e OCH2-1-naphtyl =NOH 76 
117f SMe  =NOH 132 
96 SMe  SMe  SMe  132 
118a SEt  SEt  SEt  132 
118b SPr  SPr  SPr  132 
118c SBu SBu SBu 132 
a
 The (E)-isomer 
 
 
Table 17. Position 5’ modifications of griseofulvin. 
Structure  R5’ (α) R5’ (β) Reference 
119a H CH2OH 156 
119b Me / H 135 
119c CH2-1-piperidinyl / H 135 
119d CH=NN(Me)2 / H 135 
101 CH=NOH / H 135 
119e CN / H 135 
119f CH2OH H 156,157 
97a CHO / H 133,134,135,156,157 
119g CHO Br 133 
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119h C(O)CO2Me / H 133,135 
119i C(O)CO2Et / H 133,135 
119j CH2SPh / H 135 
119k CH2SAc / H 135 
120a =CH2 135 
120b =CH-1-pyrrolidinyl 135 
120c =NNHPh 135 
98 =N2 134 
119l OH H 136,158 
119m OMe H 136 
119n OAc H 134b,136 
119o F  H 133,135b 
119p SMe / H 135 
99 SAc / H 134 
119q SO2Me / H 138 
119r 4-Tosyloxy / H 133 
119s Cl  H 133,135b 
119t Br H 133,134b,135b,138b 
119u Br CHO 133 
119v I  H 133,135b 
a
 Illustrated as the carbonyl tautomer. 
b
 Mixture of 5’ isomers / stereochemistry not defined. 
 
7.2 Tables of Isogriseofulvin Analogs 
 
 
Table 18. Position 4, 5, 6 and 7 modifications of isogriseofulvin. 
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Structure  R4 R5 R6 R7 Reference 
121a Me H OH Cl 47,49,50 
121b Me H OMe H 50 
121c Me H OMe Cl 47,49 
121d 1-Pyrrolidinyl H OMe  Cl 47,50 
121e OH H OMe Cl 41,76 
83 OMe H OH Cl 41,50 
121f OMe  H  OMe  H  45,46 
121g OMe H OMe NH2 46,50 
121h OMe H OMe NO2 46 
121i OMe  H  OEt  Cl 41,45 
121j OMe H OPr  Cl 41,45 
121k OMe  H OBu  Cl 41,45 
121l OMe  H OAll Cl 41,45 
121m OMe  H OBn  Cl 41,45 
121n OMe  H O-i-Pr  Cl 41,45 
121o OMe H OAc Cl 49 
121p OMe F OMe Cl 129 
121q OMe  NHBz  OMe  H  46 
121r OMe NO2 OMe H 46 
121s OMe  Cl  OMe  Cl 43,45,49 
121t OEt  H  OEt  Cl 24,45 
121u SMe H OMe Cl 50 
121v SMe H SMe Cl 47,49 
 
 
 
Table 19. Position 4, 5, 6, 7, 3’ and 4’ modifications of isogriseofulvin. 
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Structure R4 R5 R6 R7 R3’ R4’ Reference 
122a OMe H OH F H O-i-Pr 104 
122b OMe H OH Cl H O-i-Pr 51,104 
122c OMe H OMe F H O-i-Pr 51,104 
122d OMe  H OEt  Cl H OEt  36,45,61 
122e OMe H OBu Cl H OBu 45 
122f OMe Cl  OMe Cl Cl  OMe  43,45,49  
122g OMe Cl  OMe Cl Cl  O-i-Pr  51 
122h OMe Br  OMe Cl Br  OMe  45  
122i OEt  H OEt  Cl H OEt 24,45,49 
 
 
Table 20. Position 4’ modifications of isogriseofulvin. 
Structure  R4’ Reference 
106 H  32,45,48,49,50,53,137,152 
123a NH2 44,47,48 
123b NHMe  47,48,49 
123c NHBu  47,48 
123d NH(CH2)2NEt2 44,48 
123e NH(CH2)2-4-morpholinyl, HCl  47 
123f NEt2 47,48 
123g NMe(CH2)2NEt2 47,48 
123h 1-Pyrrolidinyl 44,47,48,49,50 
123i 1-Piperidinyl, HCl  44,47,48a 
123j 4-Morpholinyl 47,48 
123k OEt  45,49,61,76,51,147 
123l OPr  37,45,76,147 
123m OBu  37,45,61,147 
 52 
 
123n Opentyl 37 
123o Ohexyl  37,45,147 
123p Oheptyl 37 
123q Ooctyl 37 
123r Odecyl 37 
123s O(CH2)2Br  153 
123t O-i-Bu 37 
123u OCH2-cyclo-Pr 76 
123v OAll  42,45,61 
123w OBn  42,45,76 
123x OCH2-(3-methoxyC6H4) 76 
123y O-i-Pr  37,41,45,51,76,104,116 
123z O-s-Bu 37 
123aa O-cyclo-pentyl 76 
123ab OCy 37 
123ac OPh  44,45,61  
123ad SH 44,50 
123ae SMe  44,45,48,50,132 
123af SEt  44,45,132 
123ag SPr  132 
123ah SBu 132 
123ai S(CH2)2NMe2 44 
123aj S(CH2)2OH 44 
123ak S(CH2)2OAc 44 
123al SBn  44,45 
123am S-i-Pr  132 
123an SPh  44,45 
94 Cl  44,45,48,49,50,76 
a
 Not the hydrochloride 
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Table 21. Position 3’ and 4’ modifications of isogriseofulvin. 
Structure  R3’ R4’ Reference 
124a Me  OMe  42,45,49,50,152 
124b Et  OEt  42,45 
124c Pr  NH2 44 
124d Pr OMe 42,45 
124e Pr  OPr  42,45 
124f Bu OBu 37 
124g (CH2)2C(O)Me OMe  42 
124h All OMe 42,45 
124i Bn  NH2 44 
124j Bn  OMe  42,45,61,152 
124k Bn  OEt  42,45 
124l Bn  OPr  42,45 
124m Bn  OBu  42,45 
124n Bn  O(CH2)3Br  42 
124o Bn  OAll  42 
124p Bn  Cl  44,45 
124q NHBz OMe 46 
124r Cl  NH2 44 
124s Cl  OMe  43,44,45,49,51 
124t Cl  OEt  43,45 
124u Cl  OPr  43,45 
124v Cl  OBu  43,45 
124w Cl  OAll 43 
124x Cl  OBn  43 
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124y Cl  Cl  44,45 
124z Br  NH2 44 
124aa Br  OMe  43,44,45,49 
124ab Br  OEt  43,45 
124ac Br  OPr  43,45 
124ad Br  OBu  43,45 
124ae Br  OAll 43 
124af Br  OBn  43 
124ag Br  Cl  44,45 
124ah I  OMe  43,45 
124ai I  OEt  43,45 
124aj I  OPr  43,45 
124ak I  OBu  43,45 
124al I  OAll 43 
124am I  OBn  43 
 
 
7.3 Tables of Griseofulvin Acid Analogs 
 
 
Table 22. Position 6 modifications of griseofulvic acid. 
Structure  R6 Reference 
125a 1-Pyrrolidinyl 47,48 
125b OH  28,36,41,48,50,76 
125c OEt  24,48 
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125d OPr  41,48 
125e OBu  41,48 
125f Ohexadecyl 41,48 
125g O(CH2)2NEt2, HCl 41 
125h OAll  41,48 
125i OBn  41,48 
125j OCH2CO2H  41 
125k O-i-Pr  41,48 
 
 
 
Table 23. Position 4, 5, 6 and 7 modifications of griseofulvic acid. 
Structure  R4 R5 R6 R7 Reference 
126a Me H OMe Cl 47,50 
126b 1-Pyrrolidinyl H OMe Cl 47 
126c OH H OMe H 48 
126d OH H OMe Cl 41,48,50 
126e OH NO2 OH Cl 46 
126f OMe H OMe H 46,48,50 
126g OMe H OMe F 116 
126h OMe NH2 OMe H 46 
126i OMe NHBz OMe H 46,48 
126j OMe NO2 OMe Cl 46,48,144 
126k OMe F OMe Cl 129 
86 OMe Cl  OMe Cl  43,48,51,114 
126l OMe Br  OMe Cl  43,48,144 
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126m OEt H OEt Cl 24,48 
126n SMe H SMe Cl 47,48,50 
 
 
 
 
Table 24. Position 4, 5, 6, 7, 2’, 3’ and 4’ modifications of griseofulvic acid acetal analogs. 
Structure R4 R5 R6 R7 R2’ R2’ R3’ R4’ R4’ Reference 
127a Me H OMe Cl -(OCH2CH2O)- H -(OCH2CH2O)- 47 
127b NH2 H OMe Cl -(OCH2CH2O)- H -(OCH2CH2O)- 47,48 
127c NHBn H OMe Cl -(OCH2CH2O)- H -(OCH2CH2O)- 47,48 
127d NHAc H OMe Cl -(OCH2CH2O)- H -(OCH2CH2O)- 47,48 
127e 1-Pyrrolidinyl H OMe Cl -(OCH2CH2O)- H -(OCH2CH2O)- 47,48 
127f OH H OMe H -(OCH2CH2O)- H -(OCH2CH2O)- 46,48 
127g OH H OMe Cl -(OCH2CH2O)- H -(OCH2CH2O)- 41,48 
128a OMe H OH Cl -(OCH2CH2O)- H =O 41 
127h OMe H OH Cl -(OCH2CH2O)- H -(OCH2CH2O)- 41,48 
127i OMe H OMe H -(OCH2CH2O)- H -(OCH2CH2O)- 46,48 
129a OMe H OMe Cl =O H -(OCH2CH2O)- 41 
128b OMe H OMe Cl OMe / OMe OH =O 138 
128c OMe H OMe Cl -(OCH2CH2O)- H =O 41 
127j OMe H OMe Cl -(OCH2CH2O)- H -(OCH2CH2O)- 41,47,48,49 
128d OMe Br OMe Cl OMe / OAc Br =O 43 
127k SMe H SMe Cl -(OCH2CH2O)- H -(OCH2CH2O)- 47,48,49 
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Table 25. Position 5, 7 and 3’ modifications of griseofulvic acid. 
Structure  R4 R5 R7 R3’ R3’ Reference 
130a OH H Cl Bn / H 42 
130b OMe H  H  NHBz / H 46,48 
130c OMe H Cl Me  Me  42,48,49,50,75,76  
130d OMe H Cl All All 42 
130e OMe H Cl Bn  Bn  42,48 
130f OMe Cl  Cl  Cl / H 43,48,114 
85 OMe Cl  Cl  Cl  Cl  43,48 
130g OMe Br  Cl  Br / H 43,48 
130h OMe Br  Cl  Br  Br  43,48 
 
 
 
 
Table 26. Position 3’ and 5’ modifications of griseofulvic acid. 
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Structure R3’ R5’ Reference 
131a H F 133 
131b Me  H 42,48 
131c Et  H 42,48 
131d Pr  H 42,48 
131e (CH2)2C(O)Me H 42,48  
131f All H 42 
131g Bn  H 42,48,75 
131h NH2 H 46 
131i NHAc  H 46,48 
131j NHBz H 46,48 
131k NO2 H 46,48 
131l OH H 138 
131m Na H 49 
131n Cl  H 43,48,50  
131o Br  H 43,44,48 
131p I  H 43,48,144 
 
 
 
7.4 Tables of Miscellaneous Analogs of Griseofulvin 
 
 
Table 27. Position 5, 7 and 5’ modifications of 132 and 133. 
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Structure R5 R7 R5’ Reference 
132a H H H 35,51a 
132b H Cl H 31,32,45,50,51,148,151,159 
132c H Cl CH2OH 157 
132d Cl H H 51 
133a H Cl =CHOH 157 
a
 Racemic mixture 
 
Table 28. Position 7, 2’ and 4’ modifications of 134. 
Structure R7 R2’ R4’ Reference 
134a H OMe H 35 
103a H OMe OH 31,32 
134b Cl H H 137,148 
134c Cl H OH 32 
134d Cl OH  H 32,147,149 
134e Cl OH  OH 147,149 
134f Cl OH OMe 31,148 
104 Cl OMe H 31,32 
103b Cl OMe OH 31,32,50,75a,76a 
134g Cl OMe OAc 31  
a
 R
2’β
 & R
4’β
 configuration. 
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Table 29. Position 2’, 4’ and 5’ modifications of 135. 
Structure R2’ R4’ R5’ Reference 
135a OMe H H 31,32,137 
105 OMe  OH H 53a,75a,130,137,152,154 
135b OMe OH CH2OH 156
a 
135c OMe OMe H 53b,137 
135d OMe OAc H 53,137 
135e OMe OC(O)Et H 137 
135f OMe  OC(O)(CH2)2CO2H  H 154 
135g OMe OC(O)CH2OPh H 137 
135h OMe OC(O)-t-Bu H 137 
135i OMe OC(O)Ph H 137 
135j OMe OC(O)-(4-hydroxyC6H4) H 137 
135k SMe  OH  H 132 
a
 R
4’β
 configuration. 
b
 R
4’α
 configuration 
 
 
Table 30. Position 5, 7, 2’, 5’ and 6’ modifications of dehydrogriseofulvin. 
Structure R4 R5 R7 R2’ R5’ R6’ Reference 
136a Me H H OMe H Me 50 
70b OMe H H OMe H Me 51 
136b OMe H Cl H H Me 151,159 
 61 
 
136c OMe H Cl Me H Me 150 
14 OMe H Cl OMe H Me 50,51,96,107,133,151,159 
136d OMe H Cl OMe OH Me 160 
136e OMe H Cl OMe OAc Me 160 
136f OMe H Cl OPr H Me 151,159 
70c OMe H F OMe H Me 51 
136g OMe Cl H OMe H Me 51 
 
 
 
Figure 3. Additional analogs of griseofulvin (a reference in bold indicates synthetic procedure): 137a 
(ref. 137), 137b (ref. 132), 138 (ref. 138), 139 (ref. 32,36,45,50,137), 140 (ref. 137), 141a (ref. 35), 
141b (ref. 32,45,50,137,148,159), 142 (ref. 35), 143 (ref. 137) and 144 (ref. 31,45,50).  
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8. Summary and Outlook 
Since the discovery of griseofulvin in 1937, the natural product has been the subject of intensive 
research efforts including the preparation and biological evaluation of diverse analog structures. The 
recent discovery of especially the anticancer bioactivity of griseofulvin and some of its analogs holds 
promise that these spirobenzofuranones will continue to have relevance in the years to come, even as 
more modern antifungal agents are reducing the clinical use of griseofulvin in the treatment of fungal 
infections. 
We anticipate that additional analogs of griseofulvin will surface in the years to come. The advances in 
the knowledge of its biosynthesis and the exciting possibilities within fungal molecular biology 
suggests that traditional synthetic chemical methods will be supplemented by chemoenzymatic 
synthesis and analogs stemming from manipulation of fungal polyketide gene clusters. We hope that 
this review will serve as a good starting point for following this development and we look forward to 
the future of griseofulvin chemistry.  
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Captions 
Figure 1. The structure of griseofulvin 1, dechlorogriseofulvin 2 and 7-bromo-7-dechloro-griseofulvin 
3, with designation of the A, B and C ring including the IUPAC recommended numbering. 
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Figure 2. Structures of miscellaneous analogs prepared by de novo synthesis 71 (ref. 106, note: 
inconsistent data regarding stereochemistry), 72 (ref. 120), 73 (ref. 120), 74 (ref. 120), 75 (ref. 112), 76 
(ref. 112) and 77 (ref. 122). 
 
Figure 3. Additional analogs of griseofulvin (a reference in bold indicates synthetic procedure): 137a 
(ref. 137), 137b (ref. 132), 138 (ref. 138), 139 (ref. 32,36,45,50,137), 140 (ref. 137), 141a (ref. 35), 
141b (ref. 32,45,50,137,148,159), 142 (ref. 35), 143 (ref. 137) and 144 (ref. 31,45,50). 
 
Table 1. Position 4, 5, 6, 7 and 2’ modifications of griseofulvin. 
 
Table 2. Position 5, 7, 2’ and 6’ modifications of griseofulvin. 
 
Table 3. Position 5, 7 and 2’ modifications of epi-griseofulvin. 
 
Table 4. Position 5, 6, 7, 4’ and 6’ modifications of isogriseofulvin. 
 
Table 5. Position 5, 7 and 4’modifications of epi-isogriseofulvin. 
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Table 6. Position 5 and 7 modifications of 6’-desmethylgriseofulvic acid. 
 
Table 7. Position 5 and 7 modifications of epi-griseofulvic acid. 
 
Table 8. Position 4, 5, 7 and 6’ modifications of dehydrogriseofulvin. 
 
Table 9. Position 4 modifications of griseofulvin. 
 
Table 10. Position 5 modifications of griseofulvin. 
 
Table 11. Position 6 modifications of griseofulvin. 
 
Table 12. Position 4, 5, 6 and 7 modifications of griseofulvin. 
 
Table 13. Position 4, 5, 6, 2’, 3’ and 5’ modifications of griseofulvin. 
 
Table 14. Position 2’ modifications of griseofulvin. 
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Table 15. Position 2’ and 3’ modifications of griseofulvin. 
 
Table 16. Position 2’ and 4’ modifications of griseofulvin. 
 
Table 17. Position 5’ modifications of griseofulvin. 
 
Table 18. Position 4, 5, 6 and 7 modifications of isogriseofulvin. 
 
Table 19. Position 4, 5, 6, 7, 3’ and 4’ modifications of isogriseofulvin. 
 
Table 20. Position 4’ modifications of isogriseofulvin. 
 
Table 21. Position 3’ and 4’ modifications of isogriseofulvin. 
 
Table 22. Position 6 modifications of griseofulvic acid. 
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Table 23. Position 4, 5, 6 and 7 modifications of griseofulvic acid. 
 
Table 24. Position 4, 5, 6, 7, 2’, 3’ and 4’ modifications of griseofulvic acid acetal analogs. 
 
Table 25. Position 5, 7 and 3’ modifications of griseofulvic acid. 
 
Table 26. Position 3’ and 5’ modifications of griseofulvic acid. 
 
Table 27. Position 5, 7 and 5’ modifications of 132 and 133. 
 
Table 28. Position 7, 2’ and 4’ modifications of 134. 
 
Table 29. Position 2’, 4’ and 5’ modifications of 135. 
 
Table 30. Position 5, 7, 2’, 5’ and 6’ modifications of dehydrogriseofulvin. 
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Scheme 1. Proposed griseofulvin biosynthetic pathway adapted from Cacho et al. ACP is acyl carrier 
protein, NADPH is nicotinamide and SAM is S-adenosyl methionine.
94
 
 
Scheme 2. Total synthesis of racemic griseofulvin by Day et al. 
 
Scheme 3. Total synthesis of racemic griseofulvin by Brossi et al. 
 
Scheme 4. Total synthesis of racemic griseofulvin by Kuo et al. 
 
Scheme 5. Total synthesis racemic griseofulvin by Stork and Tomasz. 
 
Scheme 6. Total synthesis by Taub et al. 
 
Scheme 7. Total synthesis by Danishefsky et al. 
 
Scheme 8. Total synthesis by Yamato et al. 
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Scheme 9. Enantioselective total synthesis of griseofulvin by Pirrung et al. 
 
Scheme 10. Analog synthesis by Sargent. 
 
Scheme 11. Synthesis of 48 by Newman et al.
124
 
 
Scheme 12. Total synthesis of the 1-carbon analogs 52, 53 and 54 by Newman and Angier.
125,126
 
 
Scheme 13. Total synthesis of the 1-thio analogs 61 and 62 by Newman and Angier.
127
 
 
Scheme 14. Conversion between griseofulvin 1, griseofulvic acid 78 (drawn as the predominant 
tautomer in solution) and isogriseofulvin 79. 
 
Scheme 15. Epimerization of 1 into 22 and the suggested mechanism for the reaction. 
 
Scheme 16. Position 4 demethylation and a typical position 4 alkylation, followed by Claisen 
rearrangement of the 4-allyloxy analog. 
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Scheme 17. Position 6 demethylation of griseofulvic acid 78 followed by silver oxide mediated 
alkylation of the phenol.
41
 
 
Scheme 18. Typical halogenation with chlorine in carbon tetrachloride and de-chlorination of 
griseofulvic acid 78 or position 5 bromination/fluorination of griseofulvin 1 with bromine or the 
fluorination reagent trifluoromethyl hypofluorite, respectively.
43,129
 
 
Scheme 19. Nitration reactions and the position 7 de-chlorination from griseofulvic acid (78).
46
 
 
Scheme 20. Typical examples of conditions for synthesizing 2’- and 4’-analogs of griseofulvin 91 and 
isogriseofulvin 92 (R ≠ Me) prepared by: a) alcoholysis of griseofulvin 1 or griseofulvic acid 78; b). 
 
Scheme 21. 4’-Analogs prepared from griseofulvin 1. 
 
Scheme 22. Synthesis of the 5’-formyl analog 97 and conversion of the 5’-formyl analog into the 5’-
diazo analog 98, its derivatization and synthesis of two tetracyclic compounds from 97.
133,134,135
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Scheme 23. Typical products from hydrogen reductions of griseofulvin 1 in ethyl acetate with 10 % 
palladium on charcoal.
31
 
 
Scheme 24. Sodium borohydride reduction of griseofulvin’s 4’-oxo functionality and hydrolysis-
elimination to form the analog 106.
137
 
 
Scheme 25. Synthesis of the oxiran and cyclopropyl analogs by Newman.
138,139
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